Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant <i>Enterobacterales</i> Bloodstream Infection: a Systematic Review and Meta-Analysis
Yan Chen, Hui‐Bin Huang, Jinmin Peng, Li Weng, Bin Du
Abstract
(CRE) bloodstream infections (BSIs) remain unclear. Patients with CRE BSIs were often enrolled in small-sized clinical studies, together with other sites of infections, which reported pooled results. In this meta-analysis, the efficacy and safety were compared between CAZ-AVI and any other regimens used against CRE infections. The findings suggest that patients in the CAZ-AVI group had a significantly lower 30-day mortality than any other regimens and than colistin-based regimens. This paper provides a rationale for the use of CAZ-AVI in one of the most urgent antimicrobial-resistant infections of CRE bloodstream infections.
Topics & Concepts
Ceftazidime/avibactamBloodstream infectionMedicineAvibactamCeftazidimeMeta-analysisIntensive care medicineGram-negative bacterial infectionsMicrobiologyInternal medicinePseudomonas aeruginosaBiologyAntibioticsBacteriaGeneticsAntibiotic Resistance in BacteriaAntibiotic Use and ResistanceBacterial Identification and Susceptibility Testing